A Phase I/II Study of Biweekly Carboplatin and Nab-paclitaxel With Concurrent Radiotherapy for Patients With Locally Advanced Unresectable Stage III Non–small-cell Lung Cancer

Abstract

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial

“…Besides, the chemotherapy regimen in this study was nab-PTX, which showed promising antitumor activity in the first-line treatment of advanced gastric cancer 30 . As a potential immunomodulator, nab-PTX reverses the immunosuppressive microenvironment and promotes the cancer-immunity cycle in gastric cancer 42 , which was demonstrated to be effective in combination with concurrent radiotherapy or immunotherapy in various solid tumors 43 , 44 . Nevertheless, despite these potential reasons as well as the designed induction phase of immunotherapy plus chemotherapy in this study, the relatively high pCR rate among patients with advanced clinical tumor T stage (T3, 29.4%; T4, 71.7%) and a high proportion of lymph node metastasis (N2-3, 97.1%) demonstrated the encouraging efficacy of sintilimab in combination with cCRT for locally advanced G/GEJ adenocarcinomas, which could be further verified in future studies.…”

Comparison of post-chemoradiotherapy pneumonitis between Asian and non-Asian patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis

“…1 . Among the 248 studies, 174 studies (85 Asian and 89 non-Asian) with 20,999 patients examined definitive CRT without immunotherapy, 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 70 , 71 , 72 , 73 , 74 , 75 , 76 ,…”

Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas

“…Other clinical trials have shown that nab-paclitaxel-based chemotherapy worked as well as, or better than, other conventional drugs and regimens in advanced NSCLC (75)(76)(77)(78). Recent clinical trial results show that nab-paclitaxel-based chemoradiotherapy has promising efficacy in the treatment of locally advanced NSCLC (79)(80)(81). Furthermore, the combination of nab-paclitaxel-based chemotherapy and immunotherapy can also achieve good efficacy (82)(83)(84)(85).…”